01/20/2026
Huge congratulations to our incredible research team on the publication of this work in Pharmacological Research
This team identified RBF4 and RBF11, first-in-class compounds targeting USP11, a key driver in aggressive lymphomas and multiple cancers—using a novel approach that disrupts cancer growth while sparing healthy cells.
Highlights of their achievement:
• Discovery of a compound identical to FDA-approved Dronedarone, unlocking powerful repurposing potential
• Demonstrated strong anti-tumor activity with minimal toxicity
• Efficacy shown across 60+ cancer cell lines
This work was supported by the U.S. Department of Veterans Affairs, VCU, Richmond Institute for Veterans Research, and VCU Massey Comprehensive Cancer Center.
Proud of this team and excited to see what’s next.
Read more:
https://lnkd.in/eCr76Bvq
https://www.linkedin.com/feed/update/urn:li:activity:7419436063632453632
Huge congratulations to our incredible research team on the publication of this work in Pharmacological Research This team identified RBF4 and RBF11, first-in-class compounds targeting USP11, a key driver in aggressive lymphomas and multiple cancers—using a novel approach that disrupts cancer grow...